Cancer pill AOH1996 gives hope for destruction of solid tumors

It is still being researched, but it sounds promising: Cancer Pill AOH1996, developed by Scientists at City of Hope. In a preclinical study, the pill was found to work well in destroying all solid tumors. This unique therapy selectively disrupts DNA replication and repair in cancer cells, leaving healthy cells unaffected. It specifically targets a cancer variant of the protein PCNA, which plays a crucial role in DNA replication and repair in growing tumors.

AOH1996 is currently undergoing a Phase 1 clinical trial and preliminary results show no toxicity to normal cells, further highlighting its potential. The drug has proven effective in treating various types of cancer cells and could potentially be used in combination therapies. The study started back in 2022, and in case the results come out, we have listed the most important information about the pill.

A breakthrough in cancer therapy

City of Hope, one of America's largest cancer research and treatment organizations, was instrumental in the development of AOH1996. The new approach with AOH1996 offers the ability to selectively target proliferating cell nuclear antigen (PCNA), a protein essential in DNA replication and repair in growing tumors. Before the development of AOH1996, PCNA was considered an “incurable” target.

The drug's ability to target a cancerous variant of PCNA and leave healthy cells unaffected sets it apart from other existing treatments. Most therapies target a single pathway, allowing cancer cells to mutate and develop resistance over time. The unique mechanism of AOH1996 circumvents this problem.

From laboratory studies to clinical trials

Preclinical research has shown that AOH1996 is effective in treating cells derived from various types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancer. In addition, it can suppress tumor growth without causing toxicity when used as monotherapy or in combination with other treatments.

City of Hope is now engaged in a Phase 1 clinical trial to further evaluate the drug's efficacy and safety in humans. The clinical trial is aimed at determining the maximum tolerated dose of AOH1996 and evaluating preliminary efficacy in adults with solid tumors that have not responded to standard treatments.

Potential game-changer

One of the most promising aspects of AOH1996 is its potential use in combination therapies. In laboratory tests, the drug has been shown to increase the sensitivity of cancer cells to agents that damage DNA or chromosomes, such as the chemotherapeutic agent cisplatin. This suggests that AOH1996 could be used in combination therapies and could aid in the development of new chemotherapeutics.

Moreover, AOH1996's specific targeting of PCNA and low toxicity also make it a strong candidate for combination therapies in cancer treatment. This could potentially lower the dose of current therapeutics and minimize the overall toxicity of treatment.

Advances in cancer treatment

City of Hope's infrastructure and long research tradition helped in the development of AOH1996. This allows promising laboratory discoveries such as this one to be accelerated into clinical trials for patients in need of new treatments.

As researchers continue to investigate the mechanism of action of AOH1996, there is optimism for the future. If AOH1996 is approved by the U.S. Food and Drug Administration, it could be used in combination with existing therapies to both enhance cancer-killing effects and reduce the side effects of life-saving cancer treatments.

4x global innovation: revolutionary advances cancer treatments and Swiss breakthrough CO2 capture

In this series, we highlight the latest developments and investments in science and technology worldwide.

Read More